Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients

European Neuropsychopharmacology

Volumn 27, Issue 7, 2017, Pages 647-656

  Mas, Sergi ^a,l,m   Gassó, Patricia ^a,l,m   Torra, Mercé ^b   Bioque, Miquel ^b,m   Lobo, Antonio ^c   González Pinto, Ana ^d   Olmeda, Maria Soledad ^e   Corripio, Iluminada ^f,m   Vieta, Eduard ^a   Castro Fornieles, Josefina ^a   Rodriguez Jimenez, Roberto ^g,m   Bobes, Julio ^h,m   Usall, Judith ^i,m   Llerena, Adrián ^j,m   Saiz Ruiz, Jerónimo ^k   Bernardo, Miguel ^a,b,m   Lafuente, Amalia ^a,l,m   Rodriguez, Natalia ⁿ   Boloc, Daniel ⁿ   Bernardo, Enrique García ⁿ   Parellada, Mara ⁿ   Alonso Solís, Anna ⁿ   Rabella, Mireia ⁿ   López, Purificación ⁿ   Cengotitabengoa, Monica Martinez ⁿ   Barcones, Fe ⁿ   Zapata, Maite ⁿ   Sanjuan, Julio ⁿ   Aguilar, Eduardo J ⁿ   Balbuena, Antonio ⁿ   Bergé, Daniel ⁿ   Torrent, Carla ⁿ   Jimenez, Esther ⁿ   Baeza, Immaculada ⁿ   de la Serna, Elena ⁿ   Contreras, Fernando ⁿ   Albacete, Auria ⁿ   García Portillo, Maria Paz ⁿ   Sáiz, Pilar A ⁿ   Fraile, Miguel Gutiérrez ⁿ   Echevarría, Rafael Segarra ⁿ   Morales Muñoz, Isabel ⁿ   Dompablo, Mónica ⁿ   Butjosa, Anna ⁿ   Coromina, Marta ⁿ   Sarró, Salvador ⁿ   Landín Romero, Ramón ⁿ   Cuadrado, Angela Ibañez ⁿ   Cuesta, Manuel J ⁿ   Balanzá Martínez, Vicent ⁿ   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g Instituto de Investigación Hospital 12 de Octubre ^*  (Spain)

^h UNIVERSITY OF OVIEDO   (Spain)

ⁱ PARC SANITARI SANT JOAN DE DÉU   (Spain)

^j UNIVERSITY OF EXTREMADURA   (Spain)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^m CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

ⁿ NONE

more..

Author keywords

Antipsychotic; CYP2D6; Pharmacogenetics; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2D6; PALIPERIDONE; RISPERIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MONOTHERAPY; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PSYCHOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; FOLLOW UP; GENETICS; LONGITUDINAL STUDY; MULTICENTER STUDY; PROCEDURES; PROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; PHARMACOGENETICS; PHENOTYPE; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RISPERIDONE; YOUNG ADULT;

EID: 85017185313     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2017.03.012     Document Type: Article

References (34)

1. Berecz, R., Dorado, P., De La Rubia, A., Cáceres, M.C., Degrell, I., LLerena, A., The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. Curr. Drug Targets 5:6 (2004), 573–579.
2. Berecz, R., Llerena, A., de la Rubia, A., Gómez, J., Kellermann, M., Dorado, P., Degrell, I., Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry 35 (2002), 231–234.
3. Bernardo, M., Bioque, M., Parellada, M., Saiz Ruiz, J., Cuesta, M.J., Llerena, A., Sanjuán, J., Castro-Fornieles, J., Arango, C., Cabrera, B., PEPs Group, Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). Rev. Psiquiatr. Salud Ment. 6:1 (2013), 4–16.
4. Bioque, M., Llerena, A., Cabrera, B., Mezquida, G., Lobo, A., González-Pinto, A., Díaz-Caneja, C.M., Corripio, I., Aguilar, E.J., Bulbena, A., Castro-Fornieles, J., Vieta, E., Lafuente, A., Mas, S., Parellada, M., Saiz-Ruiz, J., Cuesta, M.J., Bernardo, M., PEPs Group, A pharmacovigilance study in first episode of psychosis: psychopharmacological interventions and safety profiles in the PEPs Project. Int. J. Neuropsychopharmacol, 2015, 10.1093/ijnp/pyv121.
5. Cohen, J., A power primer. Psychol. Bull. 112 (1992), 155–159.
6. Csordas, K., Lautner-Csorba, O., Semsei, A.F., Harnos, A., Hegyi, M., Erdelyi, D.J., Eipel, O.T., Szalai, C., Kovacs, G.T., Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia. Br. J. Haematol. 166:3 (2014), 410–420.
7. Cuesta, M.J., Sánchez-Torres, A.M., Cabrera, B., Bioque, M., Merchán-Naranjo, J., Corripio, I., González-Pinto, A., Lobo, A., Bombín, I., de la Serna, E., Sanjuan, J., Parellada, M., Saiz-Ruiz, J., Bernardo, M., PEPs Group, Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study. Schizophr. Res. 164:1–3 (2015), 65–73.
8. de Leon, J., Susce, M.T., Johnson, M., Hardin, M., Maw, L., Shao, A., Allen, A.C., Chiafari, F.A., Hillman, G., Nikoloff, D.M., DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr. 14:1 (2009), 19–34.
9. de Leon, J., Susce, M.T., Pan, R.M., Wedlund, P.J., Orrego, M.L., Diaz, F.J., A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40:3 (2007), 93–102.
10. Dorado, P., Cáceres, M., Pozo-Guisado, E., Wong, M.L., Licinio, J., Llerena, A., Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 39 (2005), S571–S574.
11. Gaedigk, A., Simon, S.D., Pearce, R.E., Bradford, L.D., Kennedy, M.J., Leeder, J.S., The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83:2 (2008), 234–242.
12. Gardner, D.M., Murphy, A.L., O׳Donnell, H., Centorrino, F., Baldessarini, R.J., International consensus study of antipsychotic dosing. Am. J. Psychiatry 167:6 (2010), 686–693.
13. Gassó, P., Mas, S., Papagianni, K., Ferrando, E., de Bobadilla, R.F., Arnaiz, J.A., Bioque, M., Bernardo, M., Lafuente, A., Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial. Pharmacogenomics 15:1 (2014), 17–28.
14. Henrard, S., Speybroeck, N., Hermans, C., Classification and regression tree analysis vs. multivariable linear and logistic regression methods as statistical tools for studying haemophilia. Haemophilia 21:6 (2015), 715–722.
15. Hou, J., Seneviratne, C., Su, X., Taylor, J., Johnson, B., Wang, X.Q., Zhang, H., Kranzler, H.R., Kang, J., Liu, L., Subgroup identification in personalized treatment of alcohol dependence. Alcohol Clin. Exp. Res. 39:7 (2015), 1253–1259.
16. Kang, R.H., Jung, S.M., Kim, K.A., Lee, D.K., Cho, H.K., Jung, B.J., Kim, Y.K., Kim, S.H., Han, C., Lee, M.S., Park, J.Y., Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J. Clin. Psychopharmacol. 29 (2009), 272–277.
17. Komossa, K., Rummel-Kluge, C., Schwarz, S., Schmid, F., Hunger, H., Kissling, W., Leucht, S., Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev., 19(1), 2011 CD006626.
18. Li, C., Xia, J., Wang, J., Risperidone dose for schizophrenia. Cochrane Database Syst. Rev., 7(4), 2009 CD007474.
19. Liu, R., Li, X., Zhang, W., Zhou, H.H., Comparison of nine statistical model based warfarin pharmacogenetic dosing algorithms using the racially diverse international warfarin pharmacogenetic consortium cohort database. PLoS One, 10(8), 2015, e0135784.
20. Llerena, A., Berecz, R., Peñas-Lledó, E., Süveges, A., Fariñas, H., Pharmacogenetics of clinical response to risperidone. Pharmacogenomics 14:2 (2013), 177–194.
21. Llerena, A., Dorado, P., Peñas-Lledó, E.M., Relevance of CYP2D6 for risperidone pharmacokinetics, pharmacodynamics and adverse reactions. Pharmacogenomics 12:3 (2011), 311–313.
22. Mannheimer, B., Holm, J., Koukel, L., Bertilsson, L., Osby, U., Eliasson, E., Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients. Eur. J. Clin. Pharmacol. 70:6 (2014), 695–699.
23. Marshall, R.J., The use of classification and regression trees in clinical epidemiology. J. Clin. Epidemiol. 54:6 (2001), 603–609.
24. Mas, S., Gassò, P., Alvarez, S., Parellada, E., Bernardo, M., Lafuente, A., Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J. 12:3 (2012), 255–259.
25. Mas, S., Llerena, A., Saíz, J., Bernardo, M., Lafuente, A., Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. Pharmacogenomics 13:15 (2012), 1773–1782.
26. Mas, S., Gassó, P., Fernández de Bobadilla, R., Arnaiz, J.A., Bernardo, M., Lafuente, A., Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. Hum. Psychopharmacol. 28:6 (2013), 586–593.
27. Nakajima, S., Uchida, H., Bies, R.R., Caravaggio, F., Suzuki, T., Plitman, E., Mar, W., Gerretsen, P., Pollock, B.G., Mulsant, B.H., Mamo, D.C., Graff-Guerrero, A., Dopamine D2/3 receptor occupancy following dose reduction is predictable with minimal plasma antipsychotic concentrations: an open-label clinical trial. Schizophr. Bull. 42:1 (2016), 212–219.
28. Pina-Camacho, L., Del Rey-Mejías, Á., Janssen, J., Bioque, M., González-Pinto, A., Arango, C., Lobo, A., Sarró, S., Desco, M., Sanjuan, J., Lacalle-Aurioles, M., Cuesta, M.J., Saiz-Ruiz, J., Bernardo, M., Parellada, M., PEPs Group, Age at first episode modulates diagnosis-related structural brain abnormalities in psychosis. Schizophr. Bull. 42:2 (2016), 344–357.
29. Roh, D., Chang, J.G., Yoon, S., Kim, C.H., Antipsychotic prescribing patterns in first-episode schizophrenia: a five-year comparison. Clin. Psychopharmacol. Neurosci 13:3 (2015), 275–282.
30. Spina, E., de Leon, J., Clinical applications of CYP genotyping in psychiatry. J. Neural. Transm. 122:1 (2015), 5–28.
31. Spina, E., de Leon, J., Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Exp. Opin. Drug Metab. Toxicol. 10:5 (2014), 721–746.
32. Swen, J.J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A.H., Mulder, H., Rongen, G.A., van Schaik, R.H., Schalekamp, T., Touw, D.J., van der Weide, J., Wilffert, B., Deneer, V.H., Guchelaar, H.J., Pharmacogenetics: from bench to byte-an update of guidelines. Clin. Pharmacol. Ther. 89 (2011), 662–673.
33. Titier, K., Bouchet, S., Pe´hourcq, F., Moore, N., Molimard, M., High-performance liquid chromatographic method with diode array detection to identify and quantify atypical antipsychotics and haloperidol in plasma after overdose. J. Chromatography B 788 (2003), 179–185.
34. van der Weide, J., van Baalen-Benedek, E.H., Kootstra-Ros, J.E., Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther. Drug Monit. 27:4 (2005), 478–483.